Pathogenesis and pharmacologic treatment of obesity: the role of energy regulatory mechanism.
Obesity has become a worldwide public health problem affecting millions of people. This is a chronic, stigmatized, and costly disease, rarely curable and is increasing in prevalence to a point today where we define obesity as an epidemic disease that not only in developed but also on developing countries. The pathogenesis of obesity is largely unknown, especially about energy regulatory mechanism that involved wide area of neuroendocrinology that is very interesting but very complex and makes internists "refuse" to learn. Obesity occurs through a longstanding imbalance between energy intake and energy expenditure, influenced by a complex biologic system that regulates appetite and adiposity. Obesity influences the pathogenesis of hypertension, type 2 diabetes, dyslipidemia, kidney, heart, and cerebrovascular disease. It is very wise for every internist to learn the pathogenesis and treatment of this worldwide diseases. Until now, the available treatments, including drugs, are palliative and are effective only while the treatment is being actively used; and besides so many side effects reported.
Manulu
Mangatas S M
MS
Departement of Internal Medicine, Faculty of Medicine, Udayana University / Sanglah Hospital, Denpasar-Bali.
Sutanegara
I N Dwi
IN
D001067:Appetite Depressants / Q000627:therapeutic use; D004734:Energy Metabolism; D054439:Ghrelin; D006706:Homeostasis; D006801:Humans; D007031:Hypothalamus / Q000502:physiology; D007328:Insulin / Q000502:physiology; D020738:Leptin / Q000502:physiology; D009765:Obesity / Q000188:drug therapy* / Q000209:etiology* / Q000378:metabolism / Q000517:prevention & control; D036361:Peptide Hormones / Q000502:physiology; D013564:Sympathetic Nervous System / Q000502:physiology
D001067:Appetite Depressants; D054439:Ghrelin; D007328:Insulin; D020738:Leptin; D036361:Peptide Hormones